SEARCH

SEARCH BY CITATION

References

  • 1
    Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: Inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:32083213.
  • 2
    Koyanagi N, Nagasu T, Fujita F, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994;54:17021706.
  • 3
    Hande K, Hagey A, Berlin J, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimiotic agent: Results of a phase I study. Clin Cancer Res 2006;12:28342840.
  • 4
    Jordan M, Toso R, Thrower D, et al. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Cell Biol 1993;90:95529556.
  • 5
    Newman S, Foster P, Stengel C, et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clin Cancer Res 2008;14:597606.
  • 6
    Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine colon 38 tumor. Cancer Chemother Pharmacol 2001;47:179184.
  • 7
    Yee K, Hagey A, Verstovsek S, et al. Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005;11:66156624.
  • 8
    Fox E, Maris J, Widemann B, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:48824887.
  • 9
    Fox E, Maris J, Widemann B. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008;14:11111115.
  • 10
    Michels J, Ellard SL, Le L, et al. A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer. Ann Oncol 2010;21:30511.
  • 11
    Mauer AM, Cohen EE, Ma PC, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008;3:631636.
  • 12
    Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 2009;101:70820. Epub 2009 May 12 Review
  • 13
    Vale D. Veterinary co-operative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v 1.0. Vet Comp Oncol 2004;2:194213.
  • 14
    Rusk A, Cozzi E, Stebbins M, et al. Cooperative activity of cytotoxic chemotherapy with antiangiogenic thrombospondin-1 peptides, ABT-526 in pet dogs with relapsed lymphoma. Clin Cancer Res 2006;12:745664.